Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

NCT00038649 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

117

Enrollment

OTHER

Sponsor class

Stopped Sponsor discontinued providing study drug.

Conditions

Myelogenous Leukemia, Chronic, Chronic Phase

Interventions

DRUG: Gleevec

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]